Phase II study of MEDI2338 for adult onset Still's disease.
Latest Information Update: 04 Aug 2022
At a glance
- Drugs Camoteskimab (Primary)
- Indications Adult-onset Still's disease
- Focus Therapeutic Use
Most Recent Events
- 01 Aug 2022 According to an Avalo Therapeutics media release, Avalo Therapeutics transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics, Apollo will assume responsibility for the future development of AVTX-007
- 03 Feb 2020 According to a Cerecor media release, the Aevi Genomic Medicine has been acquired and merged with the Cerecor.
- 22 Aug 2019 New trial record